Bio News
Switzerland-based Roche confirmed that enisefatide met the primary endpoint in a phase 2 clinical trial involving patients with diabetes.
HbA1c decreased by 2.65% in the group that received the highest 24-mg dose of enisefatide for 48 weeks.
Roche plans to begin a phase 3 trial evaluating glycemic control and a cardiovascular outcomes trial in the first half of next year.
Biobook Team
biobookmedia@biobook.co.krMinistry of Trade, Industry and Energy and Ministry of Food and Drug Safety Sign Agreement on AI Transformation and Global Competitiveness in Biotech
Paragon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
